GENIP PLC

Regulatory Filings • Jan 15, 2026

National Storage Mechanism | Additional information

RNS Number : 9340O

GenIP PLC

15 January 2026

15 January 2026

GenIP Plc

("GenIP" or the "Company")

Corporate Update

Progress in Product Adoption and Client Engagement

GenIP Plc, an AI-powered innovation intelligence and technology commercialisation company, reports continued operational progress during 2025, including approximately 330% revenue growth and 150% growth in gross margin compared with FY2024. Active clients increased by over 225%, with client retention remaining high at approximately 90%.

This performance has been driven by the rollout of the Company's integrated invention intelligence product suite and increasing adoption of its Invention Prioritizer product. Adoption in Brazil and Saudi Arabia is generating new client introductions and contributing to a growing pipeline of inbound enquiries. The Company's strategy to expand its corporate client base is progressing, with new orders secured and active discussions underway with both corporate and academic clients. Demand from Universities and other non-corporate clients remains robust, supported by repeat orders and ongoing international engagement.

Invention Prioritizer Product Order

The National Nuclear Energy Commission of Brazil (CNEN) has placed an order for the recently launched Invention Prioritizer product to assess an initial portfolio of 20 technologies for immediate delivery, with the potential, subject to performance and client requirements, to extend the engagement to a further 20 technologies.  

The Invention Prioritizer, launched in November 2024, has now been applied to a portfolio of several hundred technologies for a leading research university in Saudi Arabia. Following delivery of this assignment, the client has introduced GenIP to additional academic institutions in the region, contributing to increased inbound enquiries for this higher-margin service.  

Corporate Orders      

As part of the Company's previously announced strategy to broaden its corporate client base, GenIP has begun to secure commercial traction for its Invention Evaluator product with corporate customers.

Initial corporate orders have been secured via the recently announced partnership with 360 Impact Studio, alongside a direct corporate engagement relating to AI-based computer vision and object annotation technology. Further corporate discussions are ongoing.

Academic Orders    

Academic clients continue to demonstrate strong repeat demand for the Invention Evaluator products with new demand supported by both returning and newly engaged institutions:

●    A major US university located in one of the most active innovation and commercialisation hubs

●    A leading Chilean University - two-year engagement

●    A Singapore University recognised for its design centric research

Further discussions with Academic and other non-corporate research organisations are ongoing.

Market Engagement

In addition, the Company has launched a new webinar series, GenIP Innovation Exchange, to showcase how leading academic institutions embed GenIP's tools into their commercialisation workflows. The first session, scheduled for 27 January, will feature King Abdullah University of Science and Technology (KAUST).

Melissa Cruz, CEO of GenIP, commented:

"We are encouraged by the strong year-on-year growth in the business and the increasing use of our higher-value portfolio products. Positive feedback from existing clients is leading to inbound referrals, and our partnerships are already generating corporate orders, expanding our corporate client base. We are also in ongoing discussions with institutions we met through our 2025 event attendance and marketing efforts, which gives us confidence in the opportunity ahead."

FY 2024 was from incorporation on 23 February 2024 to 31 December 2024

For further information regarding GenIP, please visit www.genip.ai, or contact:

GenIP Plc Melissa Cruz, CEO		Via Redchurch Communications
Beaumont Cornish Limited (Nominated Adviser) Roland Cornish / Asia Szusciak / Andrew Price		Tel:  +44 (0) 20 7628 3396
AlbR Capital Limited (Broker)  Colin Rowbury Jon Belliss		Tel: +44 (0)20 7399 9427 [email protected]  [email protected]
Redchurch Communications (Financial PR) John Casey		[email protected]

The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018.

Beaumont Cornish Limited ("Beaumont Cornish") is the Company's Nominated Adviser and is authorised and regulated by the FCA. Beaumont Cornish's responsibilities as the Company's Nominated Adviser, including a responsibility to advise and guide the Company on its responsibilities under the AIM Rules for Companies and AIM Rules for Nominated Advisers, are owed solely to the London Stock Exchange. Beaumont Cornish is not acting for and will not be responsible to any other persons for providing protections afforded to customers of Beaumont Cornish nor for advising them in relation to the proposed arrangements described in this announcement or any matter referred to in it.

Notes to Editors

About GenIP

GenIP is a next-generation business      at the intersection of generative AI and innovation strategy. We empower corporates, venture funds, and research institutions to evaluate, commercialise, and scale breakthrough technologies. By combining proprietary GenAI algorithms with expert human analysis, GenIP delivers decision-grade insights and talent solutions that accelerate innovation outcomes.

Service Offerings

GenIP operates through two synergistic service lines:

Service	Description	Value Proposition
Invention Intelligence Product Suite	AI-powered market intelligence reports assessing the commercial potential of emerging technologies	Enables faster, evidence-based decisions on R&D prioritisation, investment, and IP strategy
Talent and Executive Search Services	Executive search platform using machine learning and NLP to match innovation-driven organisations with commercialisation-ready leadership	De-risks scaling by aligning technical vision with proven executive capability

Together, these services form a unified GenAI-enabled platform for innovation triage and execution.

Vision & Strategy

GenIP aims to become the global leader in generative AI analytics for innovation commercialisation. Our strategy is anchored in three growth pillars:

●    Organic Expansion

Scale Invention Evaluator and Recruitment Services through targeted outreach to corporates, VCs, and research institutions, supported by strategic marketing and digital engagement.

●    Service Deepening

Enhance functionality and margin by expanding GenAI capabilities within both service lines-unlocking new use cases and customer segments.

●    Strategic Acquisitions

Pursue bolt-on acquisitions of complementary GenAI services with validated market traction to broaden our offering and accelerate growth.

Forward looking statements

Certain statements contained in this announcement constitute forward-looking statements. When used in this announcement, the words "may", "would", "could", "will", "intend", "plan", "anticipate", "believe", "seek", "propose", "estimate", "expect", and similar expressions, as they relate to the Company, are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding intentions, beliefs or current expectations concerning, among other things, the Company's results of operations, financial position, liquidity, prospects, growth, strategies and expectations of the industry in which the Company operates.

Such statements reflect the Company's current views with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the Company's actual results, performance or achievements to materially differ from those described in this announcement Should one or more of these risks or uncertainties materialise, or should assumptions underlying forward-looking statements prove incorrect, actual results may differ materially from those described in this announcement as "intended", "planned", "anticipated", "believed", "proposed", "estimated" or "expected".

For the avoidance of doubt, the contents of the Company's website and any hyperlinks accessible from the Company's website are not incorporated by reference into, and do not form part of, this announcement and investors should not rely on them.

-ENDS-

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

UPDQZLFFQFLBBBK